# Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 3 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 10 | 7.2 | 139.5 | (66.8-256.5) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 1.8 | 332.1 | (121.3-722.9) |  |  |  |  |  |  |
| Female | 3 | 1.6 | nc | (nc-nc) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 5.4 | 92.3 | (29.8-215.5) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  | Male | 23 | 22.1 | 104.1 | (66.0-156.3) |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 25 | 22.7 | 110.0 | (71.2-162.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

265

# Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 6.9 | nc | (nc-nc) |  | Male | 6 | 5.0 | 120.6 | (44.1-262.6) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 1 | 3.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 6 | 4.5 | 134.1 | (49.0-291.9) |
| Female | 38 | 32.7 | 116.2 | (82.2-159.5) |  | Female | 2 | 3.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.2 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 8.2 | 134.7 | (67.1-241.0) |  |  |  |  |  |  |
| Female | 9 | 7.0 | 128.8 | (58.8-244.4) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 5 | 2.4 | 207.0 | (66.7-483.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 24 | 26.2 | 91.6 | (58.7-136.3) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 5.0 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 3 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 3.2 | 220.5 | (88.3-454.3) |  | Male | 0 | 2.5 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 6 | 6.6 | 90.5 | (33.1-197.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 6 | 7.6 | 79.4 | (29.0-172.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 12.5 | 143.6 | (85.1-227.0) |  | Male | 103 | 101.9 | 101.1 | (82.5-122.6) |
| Female | 7 | 13.0 | 53.7 | (21.5-110.6) |  | Female | 92 | 102.0 | 90.2 | (72.7-110.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

266

# Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 39 | 35.0 | 111.4 | (79.2-152.3) |  | Male | 33 | 23.4 | 141.1 | (97.1-198.2) |
| Female | 13 | 16.1 | 80.6 | (42.9-137.9) |  | Female | 26 | 23.0 | 113.2 | (73.9-165.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 7.4 | 134.3 | (64.3-247.0) |  | Male | 4 | 7.3 | nc | (nc-nc) |
| Female | 3 | 7.6 | nc | (nc-nc) |  | Female | 14 | 7.5 | 185.8 | (101.5-311.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.3 | nc | (nc-nc) |  | Male | 21 | 20.9 | 100.5 | (62.2-153.6) |
| Female | 164 | 179.7 | 91.3 | (77.8-106.4) |  | Female | 23 | 22.3 | 103.1 | (65.4-154.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 24 | 17.6 | 136.2 | (87.2-202.6) |
| Female | 6 | 6.0 | 100.4 | (36.7-218.6) |  | Female | 17 | 9.9 | 171.9 | (100.1-275.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 35 | 38.2 | 91.7 | (63.9-127.5) |  |  |  |  |  |  |
| Female | 35 | 46.1 | 75.9 | (52.8-105.5) |  | Female | 12 | 15.7 | 76.3 | (39.4-133.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 9.0 | 133.7 | (69.0-233.6) |  | Male | 11 | 13.2 | 83.4 | (41.6-149.2) |
| Female | 5 | 3.1 | 159.8 | (51.5-373.0) |  | Female | 15 | 16.7 | 89.6 | (50.1-147.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 145 | 108.0 | 134.3 | (113.3-158.0) |
| Female | 8 | 3.3 | 240.5 | (103.6-473.9) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 24 | 21.3 | 112.6 | (72.1-167.6) |  | Male | 13 | 8.4 | 154.9 | (82.4-265.0) |
| Female | 13 | 14.5 | 89.9 | (47.8-153.7) |  | Female | 3 | 6.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 5.3 | 113.2 | (41.3-246.4) |  | Male | 7 | 6.4 | 109.8 | (44.0-226.2) |
| Female | 5 | 2.0 | 250.7 | (80.8-585.0) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 15.0 | 86.8 | (46.2-148.4) |  | Male | 10 | 10.2 | 97.7 | (46.8-179.6) |
| Female | 13 | 13.4 | 97.4 | (51.8-166.5) |  | Female | 43 | 34.8 | 123.4 | (89.3-166.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 17 | 12.8 | 132.3 | (77.0-211.8) |  |  |  |  |  |  |
| Female | 2 | 5.5 | nc | (nc-nc) |  | Female | 44 | 41.0 | 107.4 | (78.0-144.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 77 | 61.7 | 124.7 | (98.4-155.9) |  | Male | 549 | 462.5 | 118.7 | (109.0-129.1) |
| Female | 89 | 84.0 | 106.0 | (85.1-130.4) |  | Female | 614 | 607.6 | 101.1 | (93.2-109.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

267

# Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 10.6 | 113.6 | (58.6-198.4) |  | Male | 11 | 6.8 | 162.8 | (81.2-291.3) |
| Female | 4 | 3.6 | nc | (nc-nc) |  | Female | 4 | 5.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 6 | 6.0 | 99.9 | (36.5-217.4) |
| Female | 41 | 43.5 | 94.2 | (67.6-127.8) |  | Female | 6 | 5.0 | 119.8 | (43.7-260.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 5.2 | 249.4 | (132.7-426.5) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 4 | 2.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 11.0 | 118.5 | (63.0-202.6) |  |  |  |  |  |  |
| Female | 14 | 10.1 | 138.0 | (75.4-231.6) |  | Female | 7 | 3.6 | 192.9 | (77.3-397.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 5 | 4.0 | 125.7 | (40.5-293.3) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 6 | 3.7 | 161.1 | (58.8-350.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 30 | 35.2 | 85.3 | (57.5-121.8) |
| Female | 2 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 6.3 | 78.8 | (25.4-184.0) |  | Male | 4 | 2.5 | nc | (nc-nc) |
| Female | 4 | 3.4 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 4.2 | nc | (nc-nc) |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 9 | 7.8 | 116.1 | (53.0-220.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 3.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 12 | 10.2 | 117.3 | (60.6-205.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 25 | 19.1 | 131.2 | (84.9-193.7) |  | Male | 141 | 138.5 | 101.8 | (85.7-120.1) |
| Female | 28 | 19.4 | 144.0 | (95.6-208.1) |  | Female | 163 | 140.6 | 115.9 | (98.8-135.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

268

# Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 1 | 4.5 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 5.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 2 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 3.5 | nc | (nc-nc) |  | Male | 7 | 23.0 | 30.4 | (12.2-62.6) |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 8 | 14.3 | 55.8 | (24.0-110.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

269

# Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 34 | 25.8 | 131.5 | (91.1-183.8) |  | Male | 19 | 16.3 | 116.2 | (69.9-181.5) |
| Female | 9 | 9.4 | 95.4 | (43.5-181.1) |  | Female | 16 | 12.8 | 125.3 | (71.6-203.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 4.6 | 195.3 | (89.1-370.7) |  | Male | 8 | 5.3 | 149.6 | (64.4-294.7) |
| Female | 7 | 4.2 | 168.2 | (67.4-346.5) |  | Female | 2 | 4.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 21 | 14.5 | 145.2 | (89.9-222.0) |
| Female | 122 | 106.0 | 115.0 | (95.5-137.4) |  | Female | 15 | 12.9 | 116.3 | (65.0-191.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 12.3 | 89.4 | (44.6-160.0) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 7 | 5.7 | 122.0 | (48.9-251.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 22 | 26.6 | 82.7 | (51.8-125.3) |  |  |  |  |  |  |
| Female | 22 | 26.2 | 83.8 | (52.5-126.9) |  | Female | 10 | 9.1 | 110.5 | (52.9-203.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 6.6 | 75.5 | (24.3-176.2) |  | Male | 15 | 9.6 | 155.9 | (87.2-257.2) |
| Female | 5 | 1.9 | 267.0 | (86.0-623.0) |  | Female | 9 | 9.7 | 92.6 | (42.2-175.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 83 | 80.5 | 103.1 | (82.1-127.8) |
| Female | 2 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 14.8 | 67.4 | (32.3-124.0) |  | Male | 6 | 6.0 | 99.3 | (36.3-216.1) |
| Female | 7 | 8.5 | 82.6 | (33.1-170.2) |  | Female | 4 | 3.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.9 | nc | (nc-nc) |  | Male | 4 | 2.6 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 10.1 | 89.3 | (40.8-169.6) |  | Male | 1 | 6.2 | nc | (nc-nc) |
| Female | 6 | 7.4 | 80.6 | (29.4-175.5) |  | Female | 10 | 18.0 | 55.4 | (26.5-102.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 9.3 | 75.0 | (30.1-154.6) |  |  |  |  |  |  |
| Female | 1 | 3.2 | nc | (nc-nc) |  | Female | 28 | 24.7 | 113.2 | (75.2-163.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 33 | 45.7 | 72.2 | (49.7-101.4) |  | Male | 332 | 328.9 | 100.9 | (90.4-112.4) |
| Female | 47 | 50.3 | 93.4 | (68.7-124.3) |  | Female | 356 | 351.7 | 101.2 | (91.0-112.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

270

# Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 53 | 33.5 | 158.1 | (118.4-206.8) |  | Male | 15 | 21.2 | 70.6 | (39.5-116.5) |
| Female | 18 | 13.9 | 129.4 | (76.6-204.5) |  | Female | 20 | 18.1 | 110.4 | (67.4-170.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 5.9 | 117.9 | (47.2-242.9) |  | Male | 5 | 6.9 | 73.0 | (23.5-170.3) |
| Female | 7 | 5.8 | 121.0 | (48.5-249.4) |  | Female | 5 | 6.4 | 78.0 | (25.1-182.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.2 | nc | (nc-nc) |  | Male | 36 | 18.8 | 191.6 | (134.1-265.2) |
| Female | 145 | 147.6 | 98.2 | (82.9-115.6) |  | Female | 24 | 18.7 | 128.6 | (82.4-191.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 20 | 15.4 | 130.0 | (79.3-200.7) |
| Female | 2 | 4.5 | nc | (nc-nc) |  | Female | 8 | 8.2 | 98.1 | (42.3-193.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 48 | 34.6 | 138.7 | (102.3-183.9) |  |  |  |  |  |  |
| Female | 27 | 38.9 | 69.5 | (45.8-101.1) |  | Female | 5 | 12.8 | 39.1 | (12.6-91.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 16 | 8.3 | 192.8 | (110.1-313.1) |  | Male | 18 | 12.3 | 145.8 | (86.3-230.4) |
| Female | 6 | 2.7 | 222.1 | (81.1-483.3) |  | Female | 13 | 14.5 | 89.5 | (47.6-153.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 79 | 97.2 | 81.3 | (64.3-101.3) |
| Female | 4 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 24 | 18.8 | 127.9 | (81.9-190.3) |  | Male | 3 | 7.8 | nc | (nc-nc) |
| Female | 8 | 12.0 | 66.8 | (28.8-131.7) |  | Female | 2 | 5.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 4.9 | 122.8 | (44.8-267.3) |  | Male | 10 | 4.0 | 253.0 | (121.1-465.4) |
| Female | 0 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 17 | 13.0 | 130.5 | (76.0-209.0) |  | Male | 8 | 8.1 | 98.7 | (42.5-194.5) |
| Female | 3 | 10.7 | nc | (nc-nc) |  | Female | 22 | 24.7 | 88.9 | (55.7-134.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 21 | 11.6 | 181.5 | (112.3-277.4) |  |  |  |  |  |  |
| Female | 5 | 4.6 | 109.9 | (35.4-256.4) |  | Female | 37 | 34.1 | 108.6 | (76.4-149.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 67 | 58.7 | 114.2 | (88.5-145.0) |  | Male | 506 | 417.9 | 121.1 | (110.8-132.1) |
| Female | 89 | 72.9 | 122.1 | (98.1-150.3) |  | Female | 489 | 500.6 | 97.7 | (89.2-106.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

271

# Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 2 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 3.6 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 1 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 7 | 15.0 | 46.8 | (18.7-96.4) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 11 | 10.0 | 110.3 | (55.0-197.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

272

# Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 23 | 23.2 | 99.0 | (62.8-148.6) |  | Male | 46 | 14.6 | 315.9 | (231.3-421.4) |
| Female | 12 | 8.9 | 134.9 | (69.6-235.7) |  | Female | 27 | 12.0 | 225.1 | (148.3-327.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 4.1 | 196.1 | (84.4-386.5) |  | Male | 7 | 4.7 | 149.0 | (59.7-307.1) |
| Female | 2 | 3.8 | nc | (nc-nc) |  | Female | 2 | 4.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 7 | 12.8 | 54.7 | (21.9-112.7) |
| Female | 95 | 98.7 | 96.3 | (77.9-117.7) |  | Female | 9 | 12.0 | 74.8 | (34.1-141.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 10.6 | 84.8 | (38.7-161.0) |
| Female | 0 | 3.1 | nc | (nc-nc) |  | Female | 5 | 5.4 | 93.4 | (30.1-218.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 20 | 23.7 | 84.2 | (51.4-130.1) |  |  |  |  |  |  |
| Female | 20 | 25.8 | 77.5 | (47.3-119.7) |  | Female | 9 | 8.4 | 106.8 | (48.7-202.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 5.7 | 191.4 | (95.4-342.4) |  | Male | 7 | 8.5 | 82.5 | (33.1-170.0) |
| Female | 4 | 1.7 | nc | (nc-nc) |  | Female | 1 | 9.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 1.4 | nc | (nc-nc) |  | Male | 59 | 67.3 | 87.7 | (66.7-113.1) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 12.9 | 85.1 | (42.4-152.2) |  | Male | 5 | 5.4 | 93.2 | (30.0-217.6) |
| Female | 7 | 7.8 | 89.3 | (35.8-183.9) |  | Female | 6 | 3.6 | 165.6 | (60.5-360.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.3 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 9.1 | 99.3 | (45.3-188.4) |  | Male | 2 | 5.5 | nc | (nc-nc) |
| Female | 5 | 7.1 | 70.0 | (22.5-163.3) |  | Female | 16 | 17.2 | 93.3 | (53.3-151.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 8.0 | 112.7 | (51.4-214.0) |  |  |  |  |  |  |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 23 | 21.9 | 104.9 | (66.5-157.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 33 | 40.3 | 81.8 | (56.3-114.9) |  | Male | 301 | 287.4 | 104.7 | (93.2-117.3) |
| Female | 48 | 45.8 | 104.8 | (77.3-138.9) |  | Female | 316 | 329.1 | 96.0 | (85.7-107.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

273

# Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 18.0 | 61.0 | (30.4-109.2) |  | Male | 7 | 11.6 | 60.2 | (24.1-124.1) |
| Female | 1 | 6.1 | nc | (nc-nc) |  | Female | 9 | 8.8 | 101.8 | (46.5-193.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  | Male | 2 | 3.8 | nc | (nc-nc) |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 14 | 10.1 | 138.3 | (75.6-232.1) |
| Female | 40 | 74.0 | 54.0 | (38.6-73.6) |  | Female | 4 | 8.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 8.8 | nc | (nc-nc) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 18.5 | 75.6 | (41.3-126.9) |  |  |  |  |  |  |
| Female | 9 | 17.2 | 52.3 | (23.9-99.4) |  | Female | 6 | 6.3 | 95.9 | (35.0-208.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 4.7 | nc | (nc-nc) |  | Male | 5 | 6.7 | 74.2 | (23.9-173.1) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 8 | 6.2 | 128.0 | (55.1-252.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 35 | 58.4 | 59.9 | (41.7-83.3) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 10.7 | nc | (nc-nc) |  | Male | 3 | 4.3 | nc | (nc-nc) |
| Female | 0 | 5.8 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 0 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 7.0 | 99.8 | (40.0-205.7) |  | Male | 0 | 4.5 | nc | (nc-nc) |
| Female | 2 | 4.9 | nc | (nc-nc) |  | Female | 10 | 13.5 | 74.2 | (35.5-136.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 6.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 9 | 17.4 | 51.7 | (23.6-98.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 23 | 33.1 | 69.5 | (44.0-104.3) |  | Male | 153 | 234.3 | 65.3 | (55.4-76.5) |
| Female | 26 | 33.1 | 78.5 | (51.2-115.0) |  | Female | 144 | 239.6 | 60.1 | (50.7-70.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

274

# Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 20.5 | 53.7 | (26.8-96.2) |  | Male | 13 | 13.5 | 96.1 | (51.1-164.4) |
| Female | 7 | 6.0 | 116.4 | (46.6-239.8) |  | Female | 17 | 9.6 | 176.2 | (102.6-282.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 4.0 | 125.9 | (40.6-293.9) |  | Male | 3 | 4.4 | nc | (nc-nc) |
| Female | 0 | 3.1 | nc | (nc-nc) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 12 | 11.9 | 100.7 | (52.0-176.0) |
| Female | 88 | 81.0 | 108.6 | (87.1-133.8) |  | Female | 7 | 9.0 | 78.2 | (31.3-161.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 10.7 | 74.6 | (32.1-147.0) |
| Female | 0 | 2.8 | nc | (nc-nc) |  | Female | 1 | 4.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 22.4 | 49.2 | (24.5-88.1) |  |  |  |  |  |  |
| Female | 12 | 18.3 | 65.5 | (33.8-114.5) |  | Female | 5 | 6.7 | 74.3 | (23.9-173.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.5 | nc | (nc-nc) |  | Male | 10 | 7.9 | 127.4 | (61.0-234.2) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 9 | 6.3 | 143.1 | (65.3-271.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 57 | 68.1 | 83.7 | (63.4-108.4) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 12.9 | 54.4 | (21.8-112.1) |  | Male | 6 | 5.0 | 121.0 | (44.2-263.4) |
| Female | 7 | 6.1 | 115.3 | (46.2-237.5) |  | Female | 4 | 2.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.2 | nc | (nc-nc) |  | Male | 4 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 8.3 | 96.4 | (41.5-189.9) |  | Male | 8 | 5.6 | 142.5 | (61.3-280.7) |
| Female | 4 | 5.2 | nc | (nc-nc) |  | Female | 24 | 15.9 | 150.9 | (96.7-224.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 7.7 | 64.6 | (20.8-150.7) |  |  |  |  |  |  |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 22 | 18.3 | 119.9 | (75.1-181.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 36.7 | 54.5 | (33.3-84.1) |  | Male | 213 | 273.3 | 77.9 | (67.8-89.1) |
| Female | 44 | 32.5 | 135.5 | (98.4-181.9) |  | Female | 275 | 254.6 | 108.0 | (95.6-121.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

275

# Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 5.8 | 86.0 | (27.7-200.8) |  | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 0 | 2.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 3.0 | nc | (nc-nc) |
| Female | 15 | 17.7 | 84.8 | (47.4-139.9) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 2.4 | 246.0 | (89.8-535.5) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 5.7 | 87.7 | (28.3-204.7) |  |  |  |  |  |  |
| Female | 5 | 4.4 | 113.3 | (36.5-264.3) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 0 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 16 | 16.7 | 95.9 | (54.8-155.8) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 2.1 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 2.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 5 | 4.3 | 117.4 | (37.8-274.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 10.2 | 59.1 | (21.6-128.6) |  | Male | 54 | 69.4 | 77.9 | (58.5-101.6) |
| Female | 13 | 8.6 | 150.7 | (80.2-257.7) |  | Female | 56 | 59.1 | 94.7 | (71.5-123.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

276

# Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 11 | 11.6 | 95.0 | (47.3-169.9) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 10 | 9.9 | 100.8 | (48.2-185.3) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 5 | 2.8 | 176.3 | (56.8-411.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 5.5 | nc | (nc-nc) |  | Male | 35 | 38.9 | 90.0 | (62.7-125.2) |
| Female | 4 | 5.8 | nc | (nc-nc) |  | Female | 38 | 38.9 | 97.6 | (69.1-134.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

277

# Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 6.0 | 201.0 | (103.7-351.1) |  | Male | 6 | 3.7 | 163.4 | (59.7-355.7) |
| Female | 3 | 1.7 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 19 | 20.6 | 92.2 | (55.5-144.1) |  | Female | 5 | 2.4 | 210.9 | (68.0-492.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 6.1 | 147.0 | (67.1-279.1) |  |  |  |  |  |  |
| Female | 3 | 5.0 | nc | (nc-nc) |  | Female | 5 | 1.8 | 283.5 | (91.4-661.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 5 | 2.2 | 230.3 | (74.2-537.5) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 4 | 1.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 9 | 17.3 | 51.9 | (23.7-98.5) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 2 | 3.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 4.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 10.3 | 58.3 | (21.3-126.9) |  | Male | 62 | 73.1 | 84.8 | (65.0-108.7) |
| Female | 4 | 9.0 | nc | (nc-nc) |  | Female | 55 | 66.6 | 82.6 | (62.2-107.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

278

# Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 7.1 | 196.9 | (107.5-330.3) |  | Male | 4 | 5.3 | nc | (nc-nc) |
| Female | 7 | 2.3 | 303.2 | (121.5-624.7) |  | Female | 1 | 3.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 9 | 4.7 | 192.0 | (87.6-364.5) |
| Female | 27 | 28.2 | 95.7 | (63.0-139.2) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.3 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 8.6 | 127.7 | (63.7-228.5) |  |  |  |  |  |  |
| Female | 8 | 6.6 | 121.8 | (52.5-240.1) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 2.0 | 249.7 | (80.5-582.8) |  | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 26 | 24.7 | 105.2 | (68.7-154.1) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 5.1 | 117.5 | (42.9-255.7) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 5 | 5.2 | 95.5 | (30.8-222.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 3.0 | 197.2 | (72.0-429.2) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 12 | 6.5 | 183.8 | (94.9-321.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 13.1 | 99.2 | (52.8-169.7) |  | Male | 115 | 104.0 | 110.6 | (91.3-132.7) |
| Female | 10 | 12.7 | 78.9 | (37.8-145.2) |  | Female | 98 | 91.2 | 107.5 | (87.2-131.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

279

# Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 44 | 36.9 | 119.2 | (86.6-160.0) |  | Male | 19 | 23.9 | 79.5 | (47.8-124.2) |
| Female | 12 | 13.0 | 92.4 | (47.7-161.4) |  | Female | 21 | 19.0 | 110.8 | (68.6-169.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 7.2 | nc | (nc-nc) |  | Male | 9 | 7.6 | 118.0 | (53.9-224.1) |
| Female | 2 | 6.3 | nc | (nc-nc) |  | Female | 7 | 6.0 | 116.1 | (46.5-239.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 19 | 21.3 | 89.3 | (53.7-139.4) |
| Female | 175 | 152.8 | 114.5 | (98.2-132.8) |  | Female | 13 | 18.2 | 71.4 | (38.0-122.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 17.6 | 90.7 | (51.8-147.4) |
| Female | 7 | 5.4 | 130.2 | (52.2-268.4) |  | Female | 5 | 8.0 | 62.3 | (20.1-145.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 42 | 39.5 | 106.4 | (76.7-143.9) |  |  |  |  |  |  |
| Female | 30 | 38.0 | 78.9 | (53.2-112.6) |  | Female | 13 | 12.9 | 101.1 | (53.8-172.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 9.3 | 64.8 | (23.7-141.0) |  | Male | 11 | 13.6 | 80.6 | (40.2-144.3) |
| Female | 5 | 2.5 | 197.5 | (63.6-460.9) |  | Female | 11 | 13.5 | 81.7 | (40.7-146.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 113 | 108.2 | 104.5 | (86.1-125.6) |
| Female | 2 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 29 | 21.5 | 134.7 | (90.2-193.5) |  | Male | 5 | 8.7 | 57.3 | (18.5-133.8) |
| Female | 8 | 12.0 | 66.7 | (28.7-131.5) |  | Female | 5 | 5.3 | 93.6 | (30.2-218.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 5.4 | 93.3 | (30.1-217.8) |  | Male | 4 | 5.4 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 19 | 15.1 | 125.9 | (75.8-196.6) |  | Male | 15 | 10.0 | 149.7 | (83.7-247.0) |
| Female | 13 | 10.8 | 120.2 | (64.0-205.6) |  | Female | 27 | 30.0 | 90.0 | (59.3-130.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 17 | 12.9 | 132.3 | (77.0-211.8) |  |  |  |  |  |  |
| Female | 4 | 4.3 | nc | (nc-nc) |  | Female | 29 | 33.1 | 87.7 | (58.7-126.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 55 | 63.7 | 86.4 | (65.0-112.4) |  | Male | 479 | 469.9 | 101.9 | (93.0-111.5) |
| Female | 65 | 68.6 | 94.8 | (73.2-120.8) |  | Female | 501 | 503.0 | 99.6 | (91.1-108.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

280

# Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 7 | 9.0 | 77.8 | (31.2-160.4) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 3 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 7.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 3.4 | nc | (nc-nc) |  | Male | 11 | 26.7 | 41.2 | (20.6-73.8) |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 22 | 27.8 | 79.2 | (49.6-119.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

281

# Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 36 | 28.3 | 127.2 | (89.1-176.1) |  | Male | 12 | 16.9 | 71.1 | (36.7-124.2) |
| Female | 11 | 9.5 | 116.0 | (57.8-207.5) |  | Female | 8 | 11.7 | 68.3 | (29.4-134.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 4.6 | 130.7 | (47.7-284.5) |  | Male | 1 | 5.5 | nc | (nc-nc) |
| Female | 4 | 3.7 | nc | (nc-nc) |  | Female | 6 | 4.3 | 141.2 | (51.5-307.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 15 | 14.9 | 100.7 | (56.3-166.0) |
| Female | 79 | 94.3 | 83.7 | (66.3-104.4) |  | Female | 18 | 12.3 | 146.0 | (86.5-230.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 11.6 | 85.9 | (41.1-157.9) |
| Female | 0 | 2.9 | nc | (nc-nc) |  | Female | 4 | 5.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 27 | 27.5 | 98.1 | (64.7-142.8) |  |  |  |  |  |  |
| Female | 30 | 26.2 | 114.7 | (77.4-163.8) |  | Female | 9 | 8.2 | 109.7 | (50.1-208.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 6.7 | 120.1 | (51.7-236.7) |  | Male | 12 | 10.0 | 120.0 | (61.9-209.6) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 12 | 9.9 | 121.3 | (62.6-211.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.6 | nc | (nc-nc) |  | Male | 72 | 77.5 | 93.0 | (72.7-117.1) |
| Female | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 14.4 | 83.1 | (42.9-145.2) |  | Male | 11 | 6.3 | 173.9 | (86.7-311.1) |
| Female | 5 | 7.8 | 64.0 | (20.6-149.5) |  | Female | 6 | 3.7 | 163.1 | (59.6-355.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 3.8 | 131.9 | (42.5-307.8) |  | Male | 5 | 2.7 | 186.1 | (60.0-434.4) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 10.6 | 103.9 | (51.8-185.9) |  | Male | 6 | 5.8 | 104.1 | (38.0-226.6) |
| Female | 9 | 7.1 | 126.3 | (57.6-239.8) |  | Female | 22 | 15.5 | 141.8 | (88.9-214.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 8.9 | 67.3 | (24.6-146.5) |  |  |  |  |  |  |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 22 | 21.2 | 103.7 | (65.0-157.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 48 | 48.4 | 99.2 | (73.1-131.5) |  | Male | 334 | 334.3 | 99.9 | (89.5-111.2) |
| Female | 46 | 49.1 | 93.6 | (68.5-124.9) |  | Female | 321 | 327.2 | 98.1 | (87.7-109.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

282

# Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 33 | 50.5 | 65.4 | (45.0-91.8) |  | Male | 29 | 34.5 | 84.1 | (56.3-120.7) |
| Female | 17 | 19.8 | 85.8 | (49.9-137.4) |  | Female | 26 | 31.2 | 83.4 | (54.5-122.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 12.5 | 72.1 | (32.9-137.0) |  | Male | 8 | 10.5 | 76.5 | (32.9-150.8) |
| Female | 14 | 10.8 | 129.3 | (70.6-216.9) |  | Female | 10 | 9.2 | 108.8 | (52.1-200.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 36 | 31.7 | 113.6 | (79.5-157.2) |
| Female | 195 | 222.1 | 87.8 | (75.9-101.0) |  | Female | 26 | 28.3 | 91.8 | (59.9-134.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 21 | 24.7 | 85.0 | (52.6-130.0) |
| Female | 12 | 8.3 | 144.7 | (74.7-252.7) |  | Female | 14 | 12.4 | 113.2 | (61.8-189.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 52 | 54.7 | 95.1 | (71.0-124.7) |  |  |  |  |  |  |
| Female | 45 | 57.1 | 78.9 | (57.5-105.5) |  | Female | 23 | 20.0 | 115.0 | (72.9-172.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 12.7 | 86.7 | (43.2-155.1) |  | Male | 16 | 18.7 | 85.6 | (48.9-139.0) |
| Female | 2 | 3.8 | nc | (nc-nc) |  | Female | 24 | 20.5 | 116.9 | (74.9-173.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 8 | 7.7 | 104.4 | (45.0-205.8) |  | Male | 137 | 148.6 | 92.2 | (77.4-109.0) |
| Female | 5 | 6.7 | 74.3 | (23.9-173.4) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 30 | 30.3 | 99.2 | (66.9-141.6) |  | Male | 15 | 12.0 | 124.8 | (69.8-205.9) |
| Female | 21 | 18.1 | 116.3 | (71.9-177.7) |  | Female | 13 | 8.1 | 160.6 | (85.4-274.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 7.4 | 80.8 | (29.5-175.9) |  | Male | 14 | 16.4 | 85.2 | (46.5-142.9) |
| Female | 4 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 20 | 23.4 | 85.6 | (52.3-132.2) |  | Male | 20 | 17.2 | 116.2 | (70.9-179.4) |
| Female | 17 | 17.8 | 95.4 | (55.6-152.8) |  | Female | 43 | 53.1 | 81.0 | (58.6-109.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 22 | 17.9 | 122.7 | (76.8-185.7) |  |  |  |  |  |  |
| Female | 12 | 6.7 | 179.2 | (92.5-313.1) |  | Female | 56 | 50.1 | 111.8 | (84.5-145.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 117 | 87.2 | 134.1 | (110.9-160.7) |  | Male | 648 | 676.0 | 95.9 | (88.6-103.5) |
| Female | 105 | 103.6 | 101.4 | (82.9-122.7) |  | Female | 751 | 771.6 | 97.3 | (90.5-104.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

283

# South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 20.5 | 63.5 | (33.8-108.7) |  | Male | 10 | 12.7 | 78.8 | (37.7-144.9) |
| Female | 11 | 8.3 | 132.1 | (65.8-236.3) |  | Female | 11 | 10.6 | 104.0 | (51.8-186.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.5 | nc | (nc-nc) |  | Male | 2 | 4.1 | nc | (nc-nc) |
| Female | 3 | 3.7 | nc | (nc-nc) |  | Female | 3 | 3.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 7 | 11.2 | 62.4 | (25.0-128.6) |
| Female | 91 | 85.0 | 107.1 | (86.2-131.5) |  | Female | 13 | 11.0 | 118.6 | (63.1-202.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 9.1 | 54.9 | (17.7-128.2) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 1 | 4.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 20.6 | 82.6 | (48.1-132.3) |  |  |  |  |  |  |
| Female | 32 | 23.1 | 138.5 | (94.8-195.6) |  | Female | 8 | 7.5 | 106.6 | (45.9-210.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  | Male | 2 | 7.5 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 11 | 8.7 | 126.9 | (63.2-227.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 50 | 59.2 | 84.5 | (62.7-111.4) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 11.1 | 72.3 | (31.1-142.4) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 6 | 7.0 | 85.3 | (31.2-185.7) |  | Female | 0 | 3.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 7.8 | 89.6 | (35.9-184.6) |  | Male | 3 | 4.7 | nc | (nc-nc) |
| Female | 8 | 6.6 | 122.1 | (52.6-240.6) |  | Female | 16 | 14.5 | 110.3 | (63.0-179.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 7.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.7 | nc | (nc-nc) |  | Female | 27 | 19.4 | 139.0 | (91.6-202.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 25 | 35.3 | 70.8 | (45.8-104.5) |  | Male | 194 | 251.3 | 77.2 | (66.7-88.9) |
| Female | 36 | 43.1 | 83.5 | (58.5-115.6) |  | Female | 304 | 294.1 | 103.4 | (92.1-115.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

284

# Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 8.7 | 80.8 | (32.4-166.6) |  | Male | 1 | 5.2 | nc | (nc-nc) |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 1 | 3.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 2 | 4.7 | nc | (nc-nc) |
| Female | 30 | 30.3 | 99.0 | (66.8-141.3) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 8.7 | 103.4 | (47.2-196.3) |  |  |  |  |  |  |
| Female | 7 | 6.6 | 105.4 | (42.2-217.2) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.2 | nc | (nc-nc) |  | Male | 1 | 3.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 21 | 25.8 | 81.5 | (50.4-124.6) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 4.6 | nc | (nc-nc) |  | Male | 4 | 2.0 | nc | (nc-nc) |
| Female | 4 | 2.3 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.2 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.3 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 1 | 5.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 2.9 | 171.7 | (55.3-400.7) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 9 | 7.2 | 124.4 | (56.8-236.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 14.7 | 68.1 | (32.6-125.3) |  | Male | 83 | 106.0 | 78.3 | (62.3-97.0) |
| Female | 13 | 13.4 | 97.2 | (51.7-166.2) |  | Female | 86 | 96.7 | 88.9 | (71.1-109.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

285

# Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 9.9 | 70.4 | (28.2-145.0) |  | Male | 8 | 6.9 | 116.6 | (50.2-229.7) |
| Female | 6 | 3.5 | 172.7 | (63.1-376.0) |  | Female | 4 | 5.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 4 | 2.2 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 2 | 6.0 | nc | (nc-nc) |
| Female | 50 | 43.4 | 115.3 | (85.5-152.0) |  | Female | 4 | 4.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 5.5 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 11.3 | 62.1 | (24.9-128.0) |  |  |  |  |  |  |
| Female | 7 | 10.4 | 67.6 | (27.1-139.2) |  | Female | 1 | 3.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 1 | 3.9 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 3 | 3.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 0.8 | nc | (nc-nc) |  | Male | 27 | 33.1 | 81.7 | (53.8-118.8) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 6.5 | 107.6 | (43.1-221.7) |  | Male | 0 | 2.5 | nc | (nc-nc) |
| Female | 2 | 3.4 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.6 | nc | (nc-nc) |  | Male | 3 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 4.2 | nc | (nc-nc) |  | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 4 | 2.9 | nc | (nc-nc) |  | Female | 9 | 8.4 | 106.9 | (48.8-202.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 3.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 7 | 9.5 | 73.8 | (29.6-152.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 12 | 17.9 | 67.2 | (34.7-117.3) |  | Male | 118 | 136.1 | 86.7 | (71.8-103.8) |
| Female | 13 | 18.8 | 69.2 | (36.8-118.4) |  | Female | 126 | 139.7 | 90.2 | (75.1-107.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

286

# Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 17.5 | 74.2 | (39.5-126.9) |  | Male | 11 | 11.0 | 99.7 | (49.7-178.5) |
| Female | 7 | 7.2 | 96.9 | (38.8-199.7) |  | Female | 3 | 9.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.3 | nc | (nc-nc) |  | Male | 4 | 3.5 | nc | (nc-nc) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 6 | 3.3 | 180.8 | (66.0-393.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 13 | 9.9 | 131.9 | (70.2-225.5) |
| Female | 57 | 76.8 | 74.2 | (56.2-96.1) |  | Female | 12 | 9.7 | 123.7 | (63.8-216.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 7.9 | 101.9 | (43.9-200.8) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 0 | 4.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 18.1 | 99.5 | (58.9-157.3) |  |  |  |  |  |  |
| Female | 21 | 20.5 | 102.2 | (63.2-156.2) |  | Female | 14 | 6.7 | 209.8 | (114.6-352.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 4.2 | nc | (nc-nc) |  | Male | 6 | 6.3 | 94.5 | (34.5-205.7) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 1 | 7.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 50 | 48.5 | 103.0 | (76.5-135.9) |
| Female | 4 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 9.6 | 104.0 | (49.8-191.2) |  | Male | 8 | 4.0 | 198.2 | (85.3-390.5) |
| Female | 8 | 6.2 | 128.8 | (55.4-253.7) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 2.4 | 288.2 | (115.4-593.8) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 7.1 | 126.5 | (57.7-240.2) |  | Male | 2 | 4.4 | nc | (nc-nc) |
| Female | 10 | 5.8 | 171.9 | (82.3-316.2) |  | Female | 13 | 13.8 | 94.3 | (50.1-161.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 5.9 | 136.2 | (58.6-268.4) |  |  |  |  |  |  |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 22 | 17.5 | 125.8 | (78.8-190.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 45 | 29.7 | 151.7 | (110.6-202.9) |  | Male | 240 | 215.9 | 111.2 | (97.6-126.2) |
| Female | 31 | 36.9 | 84.0 | (57.1-119.2) |  | Female | 241 | 262.3 | 91.9 | (80.6-104.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

287

# Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 12.7 | 70.6 | (32.2-134.0) |  | Male | 5 | 7.8 | 64.1 | (20.7-149.7) |
| Female | 4 | 4.3 | nc | (nc-nc) |  | Female | 3 | 5.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 3 | 6.9 | nc | (nc-nc) |
| Female | 44 | 45.6 | 96.5 | (70.1-129.6) |  | Female | 4 | 5.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 5.5 | 109.4 | (39.9-238.1) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 13.1 | 83.9 | (41.8-150.1) |  |  |  |  |  |  |
| Female | 14 | 12.5 | 112.1 | (61.3-188.2) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 2 | 4.5 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 2 | 4.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 29 | 34.4 | 84.3 | (56.4-121.0) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 6.7 | 119.1 | (51.3-234.7) |  | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 7 | 3.7 | 191.2 | (76.6-393.9) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 4.9 | nc | (nc-nc) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 6 | 3.5 | 173.6 | (63.4-377.9) |  | Female | 5 | 8.1 | 61.7 | (19.9-144.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 4.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 9 | 9.8 | 91.6 | (41.8-173.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 21.1 | 85.3 | (50.5-134.8) |  | Male | 120 | 152.6 | 78.7 | (65.2-94.0) |
| Female | 16 | 21.8 | 73.4 | (41.9-119.2) |  | Female | 133 | 155.1 | 85.8 | (71.8-101.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

288

# Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 13.1 | 145.1 | (87.3-226.6) |  | Male | 14 | 8.6 | 162.3 | (88.6-272.3) |
| Female | 10 | 4.4 | 226.3 | (108.4-416.3) |  | Female | 8 | 6.4 | 124.5 | (53.6-245.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 6 | 2.1 | 282.6 | (103.2-615.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 7 | 7.6 | 91.9 | (36.8-189.4) |
| Female | 42 | 52.9 | 79.4 | (57.2-107.4) |  | Female | 7 | 6.3 | 111.9 | (44.8-230.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 6.7 | 135.1 | (61.7-256.6) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 13.7 | 65.8 | (30.0-124.9) |  |  |  |  |  |  |
| Female | 12 | 12.4 | 96.6 | (49.9-168.7) |  | Female | 2 | 4.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.5 | nc | (nc-nc) |  | Male | 4 | 5.0 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 5 | 4.6 | 109.3 | (35.2-255.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 36 | 43.8 | 82.1 | (57.5-113.7) |
| Female | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 8.0 | 125.0 | (59.8-229.9) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 6 | 4.2 | 144.2 | (52.7-314.0) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 5.4 | 186.4 | (89.2-342.8) |  | Male | 5 | 3.6 | 139.9 | (45.1-326.5) |
| Female | 5 | 3.7 | 135.7 | (43.7-316.8) |  | Female | 10 | 9.9 | 101.4 | (48.5-186.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 5.0 | 99.5 | (32.1-232.1) |  |  |  |  |  |  |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 15 | 12.3 | 122.0 | (68.2-201.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 32 | 23.8 | 134.7 | (92.1-190.2) |  | Male | 191 | 174.9 | 109.2 | (94.3-125.9) |
| Female | 35 | 23.8 | 147.1 | (102.4-204.6) |  | Female | 189 | 173.0 | 109.3 | (94.2-126.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

289

# Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 94 | 124.8 | 75.3 | (60.9-92.2) |  | Male | 27 | 82.8 | 32.6 | (21.5-47.5) |
| Female | 36 | 48.7 | 73.9 | (51.7-102.3) |  | Female | 26 | 73.5 | 35.4 | (23.1-51.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 26 | 27.1 | 95.8 | (62.6-140.4) |  | Male | 22 | 26.5 | 83.1 | (52.1-125.9) |
| Female | 22 | 25.3 | 87.1 | (54.5-131.8) |  | Female | 30 | 23.2 | 129.5 | (87.3-184.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 4.5 | nc | (nc-nc) |  | Male | 73 | 74.0 | 98.6 | (77.3-124.0) |
| Female | 526 | 586.6 | 89.7 | (82.2-97.7) |  | Female | 74 | 69.6 | 106.3 | (83.4-133.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 73 | 62.7 | 116.4 | (91.2-146.3) |
| Female | 37 | 20.2 | 183.6 | (129.2-253.0) |  | Female | 21 | 31.1 | 67.5 | (41.8-103.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 149 | 134.5 | 110.8 | (93.7-130.0) |  |  |  |  |  |  |
| Female | 156 | 142.6 | 109.4 | (92.9-128.0) |  | Female | 41 | 50.2 | 81.6 | (58.6-110.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 30 | 32.5 | 92.4 | (62.3-131.9) |  | Male | 48 | 46.9 | 102.4 | (75.5-135.7) |
| Female | 8 | 9.6 | 83.0 | (35.7-163.5) |  | Female | 49 | 50.7 | 96.6 | (71.5-127.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 12 | 11.3 | 105.9 | (54.7-185.0) |  | Male | 310 | 385.0 | 80.5 | (71.8-90.0) |
| Female | 14 | 10.6 | 131.7 | (71.9-220.9) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 92 | 76.1 | 120.9 | (97.5-148.3) |  | Male | 38 | 29.9 | 127.3 | (90.1-174.7) |
| Female | 51 | 46.1 | 110.7 | (82.4-145.6) |  | Female | 20 | 20.1 | 99.6 | (60.8-153.8) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 19 | 18.8 | 100.8 | (60.7-157.4) |  | Male | 12 | 21.6 | 55.6 | (28.7-97.1) |
| Female | 9 | 6.3 | 143.8 | (65.6-273.0) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 47 | 54.2 | 86.7 | (63.7-115.2) |  | Male | 15 | 36.1 | 41.6 | (23.3-68.6) |
| Female | 36 | 42.5 | 84.6 | (59.3-117.1) |  | Female | 79 | 117.6 | 67.2 | (53.2-83.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 59 | 45.5 | 129.7 | (98.7-167.3) |  |  |  |  |  |  |
| Female | 17 | 16.7 | 101.6 | (59.2-162.7) |  | Female | 125 | 131.2 | 95.3 | (79.3-113.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 244 | 219.8 | 111.0 | (97.5-125.9) |  | Male | 1524 | 1645.7 | 92.6 | (88.0-97.4) |
| Female | 247 | 258.2 | 95.7 | (84.1-108.4) |  | Female | 1786 | 1931.8 | 92.5 | (88.2-96.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

290

# Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 7.0 | 170.9 | (88.2-298.6) |  | Male | 6 | 4.8 | 124.4 | (45.4-270.8) |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 3 | 4.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 4 | 1.5 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 7 | 4.3 | 162.9 | (65.3-335.7) |
| Female | 45 | 37.1 | 121.2 | (88.4-162.2) |  | Female | 1 | 4.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 4.0 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 4 | 1.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 8.2 | 85.9 | (34.4-177.0) |  |  |  |  |  |  |
| Female | 3 | 9.2 | nc | (nc-nc) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 4 | 2.7 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 5 | 3.2 | 153.9 | (49.6-359.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 38 | 25.0 | 152.0 | (107.5-208.6) |
| Female | 2 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 4.8 | 209.5 | (100.3-385.4) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 5 | 2.9 | 175.2 | (56.5-408.9) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 3.0 | 197.1 | (72.0-429.1) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 8 | 7.3 | 110.1 | (47.4-216.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 8 | 8.1 | 98.9 | (42.6-194.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 12.6 | 79.1 | (37.9-145.4) |  | Male | 126 | 98.6 | 127.8 | (106.5-152.2) |
| Female | 17 | 15.8 | 107.8 | (62.7-172.6) |  | Female | 119 | 120.8 | 98.5 | (81.6-117.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

291

# Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 3.7 | nc | (nc-nc) |  | Male | 6 | 2.2 | 268.2 | (97.9-583.8) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 5 | 1.6 | 305.3 | (98.4-712.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 2.0 | nc | (nc-nc) |
| Female | 11 | 13.6 | 80.8 | (40.3-144.5) |  | Female | 4 | 1.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 3.6 | 137.7 | (44.4-321.4) |  |  |  |  |  |  |
| Female | 6 | 3.8 | 157.9 | (57.7-343.8) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 10 | 9.9 | 100.6 | (48.2-185.0) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 6 | 3.2 | 187.1 | (68.3-407.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 6.5 | nc | (nc-nc) |  | Male | 43 | 43.6 | 98.6 | (71.3-132.8) |
| Female | 4 | 7.7 | nc | (nc-nc) |  | Female | 51 | 48.0 | 106.3 | (79.1-139.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

292

# Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 32 | 30.0 | 106.5 | (72.8-150.3) |  | Male | 11 | 18.0 | 61.0 | (30.4-109.2) |
| Female | 10 | 9.9 | 100.6 | (48.1-184.9) |  | Female | 13 | 13.5 | 96.2 | (51.2-164.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 4.9 | 141.6 | (56.7-291.8) |  | Male | 9 | 5.8 | 154.9 | (70.7-294.1) |
| Female | 5 | 4.3 | 115.0 | (37.1-268.3) |  | Female | 9 | 4.6 | 194.1 | (88.6-368.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 12 | 15.9 | 75.6 | (39.0-132.1) |
| Female | 125 | 108.7 | 115.0 | (95.7-137.0) |  | Female | 13 | 13.5 | 96.2 | (51.2-164.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 19 | 12.5 | 152.1 | (91.5-237.5) |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 8 | 6.0 | 132.9 | (57.2-261.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 32 | 29.7 | 107.8 | (73.7-152.1) |  |  |  |  |  |  |
| Female | 28 | 28.2 | 99.2 | (65.9-143.4) |  | Female | 14 | 9.5 | 147.6 | (80.6-247.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 7.1 | nc | (nc-nc) |  | Male | 8 | 10.6 | 75.4 | (32.5-148.6) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 15 | 10.4 | 144.5 | (80.8-238.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  | Male | 55 | 81.8 | 67.2 | (50.6-87.5) |
| Female | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 15.4 | 64.9 | (31.1-119.3) |  | Male | 10 | 6.8 | 148.1 | (70.9-272.5) |
| Female | 12 | 8.8 | 136.8 | (70.6-239.0) |  | Female | 5 | 4.0 | 125.4 | (40.4-292.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 4.0 | 124.5 | (40.1-290.4) |  | Male | 5 | 3.2 | 156.1 | (50.3-364.3) |
| Female | 4 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 11.3 | 115.2 | (61.3-197.1) |  | Male | 6 | 6.3 | 94.6 | (34.5-205.9) |
| Female | 9 | 7.9 | 113.4 | (51.7-215.2) |  | Female | 30 | 19.4 | 154.8 | (104.4-221.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 9.5 | 94.5 | (43.1-179.3) |  |  |  |  |  |  |
| Female | 8 | 3.3 | 239.4 | (103.1-471.7) |  | Female | 35 | 25.2 | 138.9 | (96.7-193.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 42 | 50.9 | 82.5 | (59.5-111.6) |  | Male | 327 | 356.0 | 91.9 | (82.2-102.4) |
| Female | 55 | 51.8 | 106.3 | (80.0-138.3) |  | Female | 425 | 367.0 | 115.8 | (105.1-127.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

293

# Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 33 | 35.7 | 92.4 | (63.6-129.8) |  | Male | 15 | 21.7 | 69.0 | (38.6-113.9) |
| Female | 14 | 12.8 | 109.0 | (59.5-182.9) |  | Female | 21 | 17.5 | 120.3 | (74.4-183.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 6.1 | 81.5 | (26.3-190.1) |  | Male | 10 | 7.0 | 141.9 | (67.9-261.0) |
| Female | 6 | 5.6 | 107.1 | (39.1-233.1) |  | Female | 7 | 6.0 | 116.8 | (46.8-240.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 13 | 19.3 | 67.3 | (35.8-115.1) |
| Female | 142 | 141.4 | 100.4 | (84.6-118.4) |  | Female | 24 | 17.5 | 137.1 | (87.8-204.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 15.5 | 70.7 | (35.3-126.6) |
| Female | 2 | 4.5 | nc | (nc-nc) |  | Female | 2 | 7.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 35 | 35.7 | 98.2 | (68.4-136.5) |  |  |  |  |  |  |
| Female | 42 | 36.4 | 115.5 | (83.2-156.1) |  | Female | 12 | 12.2 | 98.6 | (50.9-172.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 8.7 | 126.6 | (63.1-226.6) |  | Male | 10 | 12.9 | 77.6 | (37.1-142.7) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 17 | 13.5 | 126.0 | (73.4-201.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 91 | 103.0 | 88.4 | (71.2-108.5) |
| Female | 6 | 2.0 | 297.7 | (108.7-647.9) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 26 | 18.9 | 137.4 | (89.7-201.4) |  | Male | 9 | 8.1 | 110.8 | (50.5-210.3) |
| Female | 16 | 11.3 | 141.2 | (80.7-229.3) |  | Female | 5 | 5.1 | 97.1 | (31.3-226.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 5.0 | 180.9 | (82.5-343.4) |  | Male | 6 | 4.0 | 151.4 | (55.3-329.6) |
| Female | 3 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 13.7 | 94.7 | (50.4-161.9) |  | Male | 10 | 7.9 | 126.4 | (60.5-232.4) |
| Female | 10 | 10.2 | 97.6 | (46.7-179.5) |  | Female | 20 | 25.0 | 80.1 | (48.9-123.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 14 | 11.9 | 117.9 | (64.4-197.8) |  |  |  |  |  |  |
| Female | 2 | 4.3 | nc | (nc-nc) |  | Female | 25 | 32.8 | 76.3 | (49.4-112.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 65 | 60.7 | 107.1 | (82.7-136.5) |  | Male | 428 | 434.6 | 98.5 | (89.4-108.3) |
| Female | 55 | 66.9 | 82.2 | (61.9-106.9) |  | Female | 480 | 475.2 | 101.0 | (92.2-110.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

294

# Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 8.1 | 147.3 | (76.0-257.3) |  | Male | 5 | 5.2 | 96.0 | (30.9-224.1) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 3 | 3.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 3 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 4.6 | nc | (nc-nc) |
| Female | 30 | 34.2 | 87.8 | (59.2-125.3) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 4.0 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 8.8 | 159.0 | (86.8-266.7) |  |  |  |  |  |  |
| Female | 9 | 7.3 | 123.7 | (56.5-234.9) |  | Female | 5 | 2.8 | 178.0 | (57.3-415.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 22 | 25.3 | 86.8 | (54.4-131.4) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 4.8 | 103.4 | (33.3-241.3) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 4 | 2.1 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 8 | 6.4 | 125.9 | (54.2-248.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 8 | 7.9 | 101.0 | (43.5-199.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 13.9 | 57.7 | (24.8-113.6) |  | Male | 98 | 104.6 | 93.7 | (76.0-114.2) |
| Female | 8 | 14.2 | 56.4 | (24.3-111.1) |  | Female | 101 | 106.4 | 94.9 | (77.3-115.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

295

# Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 9.9 | 131.2 | (69.8-224.4) |  | Male | 8 | 6.6 | 121.4 | (52.3-239.1) |
| Female | 5 | 3.7 | 135.9 | (43.8-317.1) |  | Female | 8 | 5.3 | 149.7 | (64.5-295.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 5 | 2.1 | 238.0 | (76.7-555.5) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 7 | 5.8 | 120.8 | (48.4-249.0) |
| Female | 35 | 43.6 | 80.3 | (55.9-111.6) |  | Female | 3 | 5.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 5.1 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 10.8 | 83.7 | (38.2-158.9) |  |  |  |  |  |  |
| Female | 11 | 10.8 | 101.7 | (50.7-181.9) |  | Female | 1 | 3.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 2.6 | 229.3 | (83.7-499.1) |  | Male | 6 | 3.8 | 159.0 | (58.0-346.0) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 8 | 3.9 | 204.5 | (88.1-403.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 0.7 | nc | (nc-nc) |  | Male | 28 | 32.1 | 87.4 | (58.0-126.3) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 6.1 | 114.4 | (45.8-235.7) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 4.1 | 122.8 | (39.6-286.5) |  | Male | 0 | 2.8 | nc | (nc-nc) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 7 | 8.4 | 83.2 | (33.3-171.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 17 | 9.7 | 175.6 | (102.2-281.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 24 | 17.6 | 136.0 | (87.1-202.3) |  | Male | 142 | 131.6 | 107.9 | (90.9-127.2) |
| Female | 11 | 19.4 | 56.7 | (28.3-101.5) |  | Female | 133 | 143.3 | 92.8 | (77.7-110.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

296

# Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 19.8 | 65.6 | (34.9-112.2) |  | Male | 19 | 13.3 | 142.8 | (85.9-223.0) |
| Female | 1 | 6.4 | nc | (nc-nc) |  | Female | 11 | 10.0 | 110.2 | (54.9-197.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 4.0 | 176.6 | (70.8-363.9) |  | Male | 4 | 4.3 | nc | (nc-nc) |
| Female | 5 | 3.2 | 154.9 | (49.9-361.5) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 6 | 11.7 | 51.2 | (18.7-111.5) |
| Female | 114 | 83.9 | 135.9 | (112.1-163.2) |  | Female | 12 | 9.5 | 126.8 | (65.4-221.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 10.6 | nc | (nc-nc) |
| Female | 0 | 2.9 | nc | (nc-nc) |  | Female | 5 | 4.3 | 117.0 | (37.7-273.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 21.9 | 109.5 | (70.1-163.0) |  |  |  |  |  |  |
| Female | 14 | 19.3 | 72.6 | (39.6-121.7) |  | Female | 7 | 7.0 | 100.6 | (40.3-207.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 5.3 | nc | (nc-nc) |  | Male | 10 | 7.7 | 130.5 | (62.5-239.9) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 5 | 6.6 | 75.3 | (24.3-175.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 68 | 66.5 | 102.3 | (79.4-129.7) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 12.7 | 94.4 | (48.7-164.8) |  | Male | 3 | 4.8 | nc | (nc-nc) |
| Female | 8 | 6.4 | 125.9 | (54.2-248.0) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 8.2 | 85.8 | (34.4-176.7) |  | Male | 7 | 5.7 | 123.7 | (49.6-254.8) |
| Female | 5 | 5.4 | 92.6 | (29.8-216.0) |  | Female | 18 | 16.1 | 111.7 | (66.2-176.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 7.6 | 65.6 | (21.1-153.1) |  |  |  |  |  |  |
| Female | 0 | 2.3 | nc | (nc-nc) |  | Female | 16 | 18.7 | 85.4 | (48.8-138.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 35.8 | 39.1 | (21.4-65.7) |  | Male | 226 | 267.6 | 84.5 | (73.8-96.2) |
| Female | 26 | 34.5 | 75.3 | (49.2-110.3) |  | Female | 285 | 265.3 | 107.4 | (95.3-120.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

297

# Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 17 | 9.9 | 171.3 | (99.7-274.3) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 9 | 8.8 | 102.7 | (46.8-194.9) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 5 | 2.2 | 227.3 | (73.2-530.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 4.4 | nc | (nc-nc) |  | Male | 29 | 36.0 | 80.6 | (54.0-115.8) |
| Female | 2 | 4.6 | nc | (nc-nc) |  | Female | 37 | 34.2 | 108.1 | (76.1-149.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

298

# Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 10.9 | 101.3 | (50.5-181.3) |  | Male | 9 | 6.9 | 129.5 | (59.1-245.8) |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 7 | 4.6 | 150.6 | (60.3-310.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 3 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 9 | 6.2 | 145.7 | (66.5-276.6) |
| Female | 38 | 38.3 | 99.2 | (70.2-136.1) |  | Female | 3 | 4.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 5.3 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 11.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 10 | 8.6 | 115.9 | (55.5-213.1) |  | Female | 1 | 3.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 1 | 4.0 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 3.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 33 | 33.3 | 99.1 | (68.2-139.2) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 6.4 | 109.2 | (43.7-225.0) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 6 | 2.9 | 209.7 | (76.6-456.4) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 3 | 1.3 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 4.3 | 162.0 | (64.9-333.8) |  | Male | 6 | 2.8 | 212.9 | (77.7-463.4) |
| Female | 7 | 2.5 | 283.4 | (113.5-583.9) |  | Female | 6 | 7.7 | 77.7 | (28.4-169.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 15 | 8.7 | 172.3 | (96.4-284.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 18.9 | 95.4 | (56.5-150.8) |  | Male | 130 | 138.8 | 93.7 | (78.3-111.2) |
| Female | 15 | 15.1 | 99.1 | (55.5-163.5) |  | Female | 130 | 120.9 | 107.6 | (89.9-127.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

299

# Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 27 | 16.8 | 161.0 | (106.1-234.3) |  | Male | 20 | 10.5 | 190.0 | (116.0-293.5) |
| Female | 11 | 6.4 | 172.4 | (85.9-308.5) |  | Female | 16 | 8.7 | 184.2 | (105.2-299.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 0 | 3.4 | nc | (nc-nc) |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 5 | 3.0 | 168.3 | (54.2-392.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 17 | 9.3 | 183.0 | (106.6-293.1) |
| Female | 75 | 70.0 | 107.1 | (84.2-134.3) |  | Female | 11 | 8.7 | 126.7 | (63.2-226.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 7.8 | 63.8 | (20.5-148.8) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 3 | 3.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 17.4 | 109.5 | (65.9-171.0) |  |  |  |  |  |  |
| Female | 16 | 18.4 | 87.2 | (49.8-141.6) |  | Female | 5 | 6.0 | 83.4 | (26.9-194.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 4.2 | nc | (nc-nc) |  | Male | 6 | 6.2 | 97.4 | (35.6-211.9) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 6 | 6.8 | 88.6 | (32.4-192.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 62 | 50.7 | 122.3 | (93.7-156.7) |
| Female | 4 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 9.5 | 73.4 | (29.4-151.2) |  | Male | 3 | 3.9 | nc | (nc-nc) |
| Female | 4 | 5.6 | nc | (nc-nc) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 6.6 | 90.3 | (33.0-196.5) |  | Male | 7 | 4.0 | 173.5 | (69.5-357.6) |
| Female | 9 | 5.2 | 174.1 | (79.4-330.5) |  | Female | 23 | 12.5 | 184.5 | (116.9-276.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 5.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 24 | 15.9 | 150.8 | (96.6-224.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 27 | 29.1 | 92.9 | (61.2-135.2) |  | Male | 242 | 210.8 | 114.8 | (100.8-130.2) |
| Female | 31 | 32.7 | 94.9 | (64.5-134.8) |  | Female | 273 | 235.7 | 115.8 | (102.5-130.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

300

# Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 23 | 22.4 | 102.5 | (65.0-153.9) |  | Male | 8 | 14.0 | 57.3 | (24.7-112.9) |
| Female | 11 | 7.5 | 146.5 | (73.1-262.2) |  | Female | 7 | 9.9 | 70.6 | (28.3-145.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 3.9 | 154.7 | (56.5-336.7) |  | Male | 4 | 4.6 | nc | (nc-nc) |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 3 | 3.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 10 | 12.3 | 81.0 | (38.8-149.0) |
| Female | 71 | 82.2 | 86.4 | (67.5-109.0) |  | Female | 10 | 10.1 | 99.3 | (47.5-182.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 10.2 | nc | (nc-nc) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 4 | 4.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 22 | 22.6 | 97.2 | (60.9-147.2) |  |  |  |  |  |  |
| Female | 18 | 20.6 | 87.5 | (51.9-138.4) |  | Female | 7 | 7.0 | 100.3 | (40.2-206.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.6 | nc | (nc-nc) |  | Male | 11 | 8.2 | 133.6 | (66.6-239.0) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 7 | 7.7 | 90.4 | (36.2-186.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.3 | nc | (nc-nc) |  | Male | 76 | 67.6 | 112.5 | (88.6-140.8) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 12.5 | 128.3 | (73.3-208.4) |  | Male | 4 | 5.2 | nc | (nc-nc) |
| Female | 7 | 6.6 | 105.8 | (42.4-218.1) |  | Female | 5 | 2.9 | 171.4 | (55.2-399.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 5 | 2.3 | 213.9 | (68.9-499.2) |
| Female | 2 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 8.6 | nc | (nc-nc) |  | Male | 6 | 5.2 | 115.6 | (42.2-251.7) |
| Female | 6 | 5.7 | 106.0 | (38.7-230.8) |  | Female | 12 | 14.1 | 84.9 | (43.8-148.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 7.8 | 90.1 | (36.1-185.6) |  |  |  |  |  |  |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 13 | 19.0 | 68.4 | (36.4-117.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 42 | 39.3 | 106.7 | (76.9-144.3) |  | Male | 285 | 279.8 | 101.9 | (90.4-114.4) |
| Female | 37 | 40.5 | 91.4 | (64.3-126.0) |  | Female | 243 | 274.9 | 88.4 | (77.6-100.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

301

# Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 54 | 56.6 | 95.3 | (71.6-124.4) |  | Male | 28 | 37.5 | 74.6 | (49.6-107.8) |
| Female | 26 | 22.4 | 116.1 | (75.8-170.1) |  | Female | 24 | 31.4 | 76.4 | (48.9-113.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 13 | 11.5 | 112.8 | (60.0-192.9) |  | Male | 8 | 12.1 | 66.1 | (28.5-130.2) |
| Female | 8 | 10.2 | 78.5 | (33.8-154.8) |  | Female | 11 | 10.5 | 105.0 | (52.3-187.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 2.0 | nc | (nc-nc) |  | Male | 34 | 33.3 | 102.1 | (70.7-142.7) |
| Female | 241 | 250.9 | 96.1 | (84.3-109.0) |  | Female | 30 | 30.8 | 97.4 | (65.7-139.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 46 | 29.0 | 158.8 | (116.2-211.8) |
| Female | 9 | 8.3 | 108.0 | (49.3-205.0) |  | Female | 13 | 13.7 | 94.8 | (50.4-162.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 65 | 60.7 | 107.1 | (82.6-136.5) |  |  |  |  |  |  |
| Female | 73 | 64.6 | 113.1 | (88.6-142.1) |  | Female | 15 | 21.7 | 69.0 | (38.6-113.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 20 | 15.0 | 133.4 | (81.4-206.0) |  | Male | 13 | 21.5 | 60.5 | (32.2-103.5) |
| Female | 1 | 4.4 | nc | (nc-nc) |  | Female | 24 | 23.4 | 102.4 | (65.6-152.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 8 | 4.6 | 174.4 | (75.1-343.7) |  | Male | 134 | 182.8 | 73.3 | (61.4-86.8) |
| Female | 4 | 4.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 36 | 34.9 | 103.2 | (72.3-142.9) |  | Male | 16 | 13.6 | 117.8 | (67.3-191.2) |
| Female | 14 | 20.1 | 69.6 | (38.0-116.8) |  | Female | 10 | 9.1 | 110.5 | (52.9-203.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 11 | 8.8 | 125.4 | (62.5-224.4) |  | Male | 8 | 8.6 | 92.6 | (39.9-182.5) |
| Female | 7 | 2.8 | 252.4 | (101.1-520.0) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 19 | 23.6 | 80.7 | (48.5-126.0) |  | Male | 19 | 15.9 | 119.5 | (71.9-186.6) |
| Female | 12 | 18.4 | 65.0 | (33.6-113.6) |  | Female | 61 | 47.0 | 129.9 | (99.3-166.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 29 | 21.4 | 135.8 | (90.9-195.0) |  |  |  |  |  |  |
| Female | 10 | 7.6 | 132.4 | (63.4-243.4) |  | Female | 58 | 57.1 | 101.6 | (77.1-131.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 135 | 101.4 | 133.1 | (111.6-157.5) |  | Male | 766 | 752.7 | 101.8 | (94.7-109.2) |
| Female | 123 | 116.5 | 105.6 | (87.8-126.0) |  | Female | 834 | 842.6 | 99.0 | (92.4-105.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

302

# Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 11.0 | 72.8 | (31.3-143.4) |  | Male | 5 | 6.8 | 73.1 | (23.6-170.7) |
| Female | 4 | 3.2 | nc | (nc-nc) |  | Female | 2 | 4.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 2 | 6.1 | nc | (nc-nc) |
| Female | 30 | 38.5 | 77.9 | (52.6-111.2) |  | Female | 3 | 4.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 5.2 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 11.4 | 61.4 | (24.6-126.4) |  |  |  |  |  |  |
| Female | 7 | 9.2 | 76.0 | (30.4-156.5) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 2 | 4.1 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 23 | 34.6 | 66.5 | (42.1-99.7) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 6.3 | 111.5 | (44.7-229.8) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 4.3 | 117.6 | (37.9-274.5) |  | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 6 | 6.9 | 87.1 | (31.8-189.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 3.8 | 130.1 | (41.9-303.6) |  |  |  |  |  |  |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 10 | 8.9 | 112.3 | (53.8-206.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 18.9 | 105.8 | (64.6-163.5) |  | Male | 105 | 139.3 | 75.4 | (61.6-91.2) |
| Female | 18 | 17.8 | 101.0 | (59.8-159.7) |  | Female | 108 | 125.6 | 86.0 | (70.5-103.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

303

# Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 36 | 33.3 | 108.1 | (75.7-149.6) |  | Male | 19 | 22.0 | 86.5 | (52.0-135.0) |
| Female | 12 | 12.8 | 93.9 | (48.5-164.1) |  | Female | 19 | 17.7 | 107.2 | (64.5-167.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 6.4 | 124.1 | (53.4-244.5) |  | Male | 7 | 7.0 | 99.8 | (40.0-205.6) |
| Female | 7 | 5.8 | 121.6 | (48.7-250.5) |  | Female | 5 | 5.9 | 84.1 | (27.1-196.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 17 | 19.3 | 88.0 | (51.2-140.9) |
| Female | 136 | 146.1 | 93.1 | (78.1-110.1) |  | Female | 21 | 17.6 | 119.4 | (73.9-182.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 20 | 16.9 | 118.5 | (72.4-183.1) |
| Female | 7 | 4.7 | 150.0 | (60.1-309.0) |  | Female | 9 | 7.8 | 115.2 | (52.6-218.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 34 | 35.7 | 95.3 | (66.0-133.2) |  |  |  |  |  |  |
| Female | 32 | 36.0 | 88.9 | (60.8-125.5) |  | Female | 11 | 12.4 | 88.6 | (44.2-158.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 8.7 | 149.8 | (79.7-256.2) |  | Male | 14 | 12.6 | 110.9 | (60.6-186.0) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 11 | 13.2 | 83.6 | (41.7-149.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 102 | 106.0 | 96.2 | (78.5-116.8) |
| Female | 3 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 30 | 20.3 | 148.0 | (99.8-211.2) |  | Male | 8 | 8.0 | 100.4 | (43.2-197.8) |
| Female | 11 | 11.6 | 94.9 | (47.3-169.7) |  | Female | 3 | 5.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 5.1 | nc | (nc-nc) |  | Male | 5 | 4.5 | 110.9 | (35.7-258.9) |
| Female | 1 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 20 | 13.5 | 148.0 | (90.4-228.7) |  | Male | 11 | 9.1 | 121.5 | (60.6-217.5) |
| Female | 12 | 10.1 | 118.3 | (61.0-206.6) |  | Female | 28 | 26.4 | 106.2 | (70.6-153.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 12.4 | 96.6 | (49.9-168.8) |  |  |  |  |  |  |
| Female | 2 | 4.3 | nc | (nc-nc) |  | Female | 30 | 33.3 | 90.2 | (60.8-128.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 73 | 59.8 | 122.1 | (95.7-153.6) |  | Male | 473 | 437.8 | 108.0 | (98.5-118.2) |
| Female | 81 | 68.5 | 118.3 | (93.9-147.0) |  | Female | 483 | 483.1 | 100.0 | (91.3-109.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

304

# Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 3.1 | 192.1 | (70.2-418.2) |  | Male | 6 | 2.2 | 267.2 | (97.6-581.6) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 7 | 2.0 | 341.5 | (136.8-703.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 25 | 16.7 | 149.8 | (96.9-221.2) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 1.8 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 3.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 7 | 3.7 | 188.1 | (75.4-387.6) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 4 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 13 | 11.3 | 114.9 | (61.1-196.5) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 2.2 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 2 | 3.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 3.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 5.9 | nc | (nc-nc) |  | Male | 56 | 45.3 | 123.7 | (93.5-160.7) |
| Female | 11 | 7.4 | 148.4 | (74.0-265.5) |  | Female | 74 | 54.1 | 136.9 | (107.5-171.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

305

# Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 2.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 9 | 11.5 | 78.3 | (35.7-148.7) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 8.9 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

306

# Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 9.6 | nc | (nc-nc) |  | Male | 5 | 5.9 | 85.3 | (27.5-199.2) |
| Female | 4 | 3.5 | nc | (nc-nc) |  | Female | 8 | 4.3 | 184.7 | (79.5-364.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 1.6 | 383.2 | (139.9-834.1) |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 3 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 6 | 5.1 | 117.3 | (42.8-255.3) |
| Female | 36 | 35.5 | 101.4 | (71.0-140.4) |  | Female | 1 | 4.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 9.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 9.8 | 61.2 | (22.4-133.3) |  | Female | 4 | 3.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 3.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 19 | 28.0 | 67.8 | (40.8-105.8) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 5.2 | 154.1 | (66.3-303.6) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 4 | 5.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 5 | 7.8 | 64.2 | (20.7-149.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 16.9 | 76.8 | (40.8-131.3) |  | Male | 85 | 116.9 | 72.7 | (58.1-89.9) |
| Female | 11 | 17.9 | 61.4 | (30.6-109.9) |  | Female | 105 | 121.3 | 86.5 | (70.8-104.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

307

# Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 8.4 | 166.1 | (90.7-278.7) |  | Male | 3 | 5.9 | nc | (nc-nc) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 8 | 4.5 | 177.1 | (76.3-349.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 3 | 1.5 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 9 | 5.3 | 170.8 | (77.9-324.3) |
| Female | 35 | 37.0 | 94.5 | (65.8-131.5) |  | Female | 2 | 4.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 5.1 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 4 | 1.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 9.7 | 103.2 | (49.4-189.8) |  |  |  |  |  |  |
| Female | 17 | 8.2 | 206.8 | (120.4-331.1) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 2.5 | 324.4 | (139.7-639.2) |  | Male | 4 | 3.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 2.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 23 | 32.3 | 71.1 | (45.1-106.8) |
| Female | 2 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 5.9 | 168.4 | (80.6-309.7) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 5 | 2.8 | 177.8 | (57.3-414.9) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.7 | nc | (nc-nc) |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 9 | 7.6 | 118.3 | (54.0-224.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 3 | 8.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 15.6 | 96.2 | (53.8-158.7) |  | Male | 130 | 122.8 | 105.9 | (88.5-125.7) |
| Female | 16 | 14.8 | 108.0 | (61.7-175.4) |  | Female | 128 | 116.9 | 109.5 | (91.3-130.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

308

# Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 3.5 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 4 | 1.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 2 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 13 | 12.7 | 102.1 | (54.3-174.6) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 3.4 | 175.4 | (64.1-381.8) |  |  |  |  |  |  |
| Female | 4 | 2.8 | nc | (nc-nc) |  | Female | 3 | 1.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 2 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 7 | 11.5 | 60.8 | (24.4-125.2) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 1.3 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 6.1 | 97.9 | (35.7-213.0) |  | Male | 40 | 43.5 | 91.9 | (65.7-125.2) |
| Female | 3 | 6.3 | nc | (nc-nc) |  | Female | 46 | 41.2 | 111.7 | (81.8-149.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

309

# Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 8.9 | 67.3 | (24.6-146.6) |  | Male | 5 | 6.8 | 73.1 | (23.6-170.6) |
| Female | 7 | 3.3 | 215.3 | (86.2-443.6) |  | Female | 4 | 5.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 6 | 6.1 | 98.3 | (35.9-213.9) |
| Female | 50 | 46.1 | 108.4 | (80.4-142.9) |  | Female | 3 | 5.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 6.1 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 11.3 | 105.9 | (54.7-185.1) |  |  |  |  |  |  |
| Female | 6 | 10.5 | 57.2 | (20.9-124.5) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 3 | 3.8 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 3.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 37 | 36.4 | 101.6 | (71.5-140.0) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 7.0 | 114.1 | (49.1-224.8) |  | Male | 5 | 2.4 | 209.8 | (67.6-489.5) |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 4.1 | 145.1 | (53.0-315.8) |  | Male | 1 | 3.5 | nc | (nc-nc) |
| Female | 5 | 3.0 | 164.1 | (52.9-383.0) |  | Female | 4 | 10.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 11 | 10.1 | 109.2 | (54.5-195.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 16.8 | 130.7 | (81.9-197.9) |  | Male | 139 | 139.6 | 99.6 | (83.7-117.6) |
| Female | 22 | 17.1 | 128.3 | (80.4-194.2) |  | Female | 140 | 144.5 | 96.9 | (81.5-114.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

310

# Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 3.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 5 | 12.3 | 40.7 | (13.1-94.9) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 7 | 10.9 | 64.5 | (25.8-132.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

311

# Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 7.2 | 83.4 | (30.4-181.4) |  | Male | 4 | 5.1 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 3 | 4.5 | nc | (nc-nc) |
| Female | 44 | 30.6 | 143.8 | (104.5-193.0) |  | Female | 5 | 3.3 | 153.1 | (49.3-357.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.3 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 8.3 | 72.1 | (26.3-156.9) |  |  |  |  |  |  |
| Female | 3 | 6.5 | nc | (nc-nc) |  | Female | 5 | 2.6 | 195.4 | (63.0-456.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 2.1 | nc | (nc-nc) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 6 | 2.2 | 276.9 | (101.1-602.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 26 | 26.4 | 98.4 | (64.3-144.2) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 5.0 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 7 | 6.4 | 108.9 | (43.6-224.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 3.1 | 160.5 | (51.7-374.6) |  |  |  |  |  |  |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 12 | 6.9 | 174.8 | (90.2-305.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 13.3 | 105.5 | (57.7-177.1) |  | Male | 93 | 103.4 | 90.0 | (72.6-110.2) |
| Female | 18 | 12.0 | 150.0 | (88.9-237.1) |  | Female | 125 | 94.8 | 131.8 | (109.7-157.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

312

# Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 10.1 | 178.6 | (105.8-282.3) |  | Male | 11 | 7.3 | 150.0 | (74.8-268.4) |
| Female | 5 | 5.1 | 97.4 | (31.4-227.3) |  | Female | 4 | 7.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.4 | nc | (nc-nc) |  | Male | 5 | 2.3 | 213.9 | (68.9-499.1) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 4 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 8 | 6.6 | 122.0 | (52.6-240.5) |
| Female | 64 | 60.5 | 105.8 | (81.5-135.2) |  | Female | 6 | 7.2 | 83.4 | (30.5-181.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 6.1 | 261.3 | (149.3-424.4) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 11.9 | 143.0 | (83.2-228.9) |  |  |  |  |  |  |
| Female | 11 | 15.1 | 73.0 | (36.4-130.6) |  | Female | 9 | 5.2 | 173.5 | (79.2-329.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 3 | 5.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 51 | 37.8 | 134.8 | (100.4-177.2) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 16 | 7.2 | 221.5 | (126.5-359.7) |  | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 5 | 4.8 | 105.0 | (33.9-245.1) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 4 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 4.6 | 131.1 | (47.9-285.3) |  | Male | 1 | 3.6 | nc | (nc-nc) |
| Female | 5 | 4.3 | 116.5 | (37.5-271.8) |  | Female | 9 | 11.4 | 79.1 | (36.1-150.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 4.4 | 112.6 | (36.3-262.9) |  |  |  |  |  |  |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 12 | 13.7 | 87.8 | (45.3-153.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 26 | 18.8 | 138.3 | (90.3-202.6) |  | Male | 218 | 148.9 | 146.4 | (127.6-167.2) |
| Female | 28 | 26.9 | 104.1 | (69.2-150.5) |  | Female | 188 | 199.2 | 94.4 | (81.4-108.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

313

# Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 27 | 31.9 | 84.7 | (55.8-123.3) |  | Male | 19 | 20.1 | 94.3 | (56.8-147.3) |
| Female | 12 | 10.1 | 118.9 | (61.4-207.8) |  | Female | 22 | 14.6 | 150.3 | (94.1-227.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 5.8 | 138.4 | (59.6-272.7) |  | Male | 4 | 6.5 | nc | (nc-nc) |
| Female | 6 | 4.7 | 126.6 | (46.2-275.6) |  | Female | 4 | 4.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 11 | 17.7 | 62.2 | (31.0-111.3) |
| Female | 127 | 118.5 | 107.2 | (89.4-127.5) |  | Female | 15 | 14.1 | 106.2 | (59.4-175.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 15 | 14.3 | 105.2 | (58.8-173.5) |
| Female | 2 | 3.9 | nc | (nc-nc) |  | Female | 7 | 6.4 | 109.5 | (43.9-225.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 30 | 32.1 | 93.4 | (63.0-133.3) |  |  |  |  |  |  |
| Female | 29 | 29.3 | 99.0 | (66.3-142.2) |  | Female | 7 | 10.2 | 68.9 | (27.6-142.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 7.9 | 113.7 | (51.9-215.8) |  | Male | 11 | 11.6 | 94.8 | (47.3-169.7) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 10 | 10.6 | 94.8 | (45.4-174.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 53 | 90.8 | 58.4 | (43.7-76.4) |
| Female | 1 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 17.6 | 62.4 | (31.1-111.6) |  | Male | 5 | 7.4 | 67.8 | (21.8-158.1) |
| Female | 12 | 9.3 | 128.4 | (66.3-224.3) |  | Female | 2 | 4.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 4.6 | nc | (nc-nc) |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 12.5 | 144.1 | (85.3-227.7) |  | Male | 8 | 7.7 | 103.9 | (44.7-204.7) |
| Female | 7 | 8.3 | 83.9 | (33.6-172.9) |  | Female | 21 | 22.6 | 93.1 | (57.6-142.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 10.8 | 73.9 | (31.8-145.6) |  |  |  |  |  |  |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 24 | 27.1 | 88.5 | (56.7-131.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 38 | 56.5 | 67.3 | (47.6-92.3) |  | Male | 304 | 394.9 | 77.0 | (68.6-86.1) |
| Female | 57 | 53.3 | 107.0 | (81.0-138.6) |  | Female | 396 | 391.3 | 101.2 | (91.5-111.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

314

# Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 8 | 8.9 | 89.4 | (38.5-176.2) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 7 | 2.0 | 352.1 | (141.1-725.4) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 5 | 7.5 | 66.8 | (21.5-155.9) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 5 | 2.2 | 230.5 | (74.3-538.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 4.1 | nc | (nc-nc) |  | Male | 21 | 30.3 | 69.3 | (42.9-106.0) |
| Female | 2 | 3.7 | nc | (nc-nc) |  | Female | 30 | 28.4 | 105.7 | (71.3-150.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

315